News
Press Releases
.jpg)
-
- 11
- 2022/01
Sino Biopharm Wins"Best lR Award"
On January 11, 2022, Mr. Tse Hsin, Executive Director and Senior Vice President of Sino Biopharm, was awarded the "Best lR Award" at the "2022 Global Investment Trends Forum and the 6th Golden Hong Kong Stock Awards Ceremony" held in Shenzhen.View > -
- 21
- 2021/12
Innovative Medicine "TCR1672" obtained Approval for Clinical Trial
Recently, “TCR1672”, a second-generation, highly selective P2X3 receptor antagonist self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration of China to commence clinical trial for refractory chronic cough (RCC) in China.View > -
- 20
- 2021/12
Exclusive Sales Agreement of Penpulimab Monoclonal Antibody
Dec 20, Sino Biopharm announces that the Group has entered into an exclusive sales agreement of Penpulimab monoclonal antibody with its associate CTTQ-Akeso (Shanghai) Biomed. Tech. Co., Ltd. and the associate’s shareholder Akeso Biopharma Co., Ltd.View > -
- 15
- 2021/11
Sino Biopharm welcomes the relocation of its headquarters in Beijing
On November 15, 2021, Sino Biopharm Beijing headquarters was officially relocated to the new office area of the North Tower of CP center in Beijing CBD, opening a new journey for the development of the group in the commercial core area.View > -
- 29
- 2021/06
Tenofovir Alafenamide Fumarate Tablets obtains Drug Registration Certificate
Recently, “tenofovir alafenamide fumarate tablets” (Brand name: Qinglide （晴力得）), a new drug developed by the Group for the treatment of hepatitis B, has obtained drug registration certificate granted by the National Medical Products Administration of the People’s Republic of China.View > -
- 02
- 2021/06
“Tolvaptan Tablets” obtains Drug Registration Certificate
Recently, “Tolvaptan Tablets” (Brand name: Xinsuan), a new diuretic drug developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the People’s Republic of China and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs.View > -
- 27
- 2021/05
“Sunitinib Malate Capsules” obtains Drug Registration Certificate
Recently, “Sunitinib Malate Capsules” (brand name: Qingnishu (晴尼舒)) (approved specification: 12.5mg), a key product in the field of oncology developed by the Group, has obtained the drug registration certificate from the National Medical Products Administration of the People’s Republic of China.View > -
- 24
- 2021/05
Penpulimab Selected under The New Policy of Real-Time Oncology Review of FDA and BLA Submitted for Third-Line Treatment of Nasopharyngeal Carcinoma
Recently, Penpulimab (research and development code: AK105), an PD-1 monoclonal antibody drug co-developed by the Group with Akeso, Inc., has submitted a Biologics License Application (“BLA”) to the Food and Drug Administration of the United States (“FDA”) for third-line treatment of metastatic nasopharyngeal carcinoma.View > -
- 03
- 2020/06
“Linezolid and Glucose Injection” Passes Consistency Evaluation
Recently, “Linezolid and Glucose Injection” (Brand name: Tianli), an antibacterial drug developed by the Group, has obtained the notice of approval of supplemental application on pharmaceutical product issued by the National Medical Products Administration of the People’s Republic of China, and passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs.View >